11 C
Lancashire
Saturday, November 2, 2024

Charles River Laboratories Opens Cutting-edge Cell and Gene Therapy Manufacturing Facility at Alderley Park

Site will support therapeutic developers with rapid access to plasmid DNA, a critical starting material

Alderley Park, UK – 20th October 2022 – Charles River Laboratories International, Inc. (NYSE: CRL) has today officially opened the doors of its Alderley Park site in Cheshire, United Kingdom, a purpose-built High Quality (HQ) plasmid manufacturing facility to support the development of potentially transformative cell and gene therapies (C&GTs).

To meet increasing demand for C&GTs with accelerated clinical development, there is a need for manufacturers to rapidly supply phase-appropriate plasmid DNA, a critical starting material, to therapeutic developers. Charles River offers three grades of plasmid DNA: research, HQ, and GMP, to transition seamlessly throughout your program development journey.

HQ plasmid is manufactured by Charles River to the principles of GMP, with the added benefit of an industry-leading 5+ week turnaround from initiation to release, reducing time to clinic.

With an established quality infrastructure and 20+ year track record, the facility, based within the Alderley Park campus, is the latest in Charles River’s growing global contract development and manufacturing (CDMO) network. The site will help ensure demand for these DNA vectors can be met, furthermore supporting the growth of the industry in the UK.

Niall Dinwoodie, Executive Director, Gene Manufacturing Europe, Charles River: “The new 16,000 square foot facility expands our capabilities and will help fast-track the process of bringing therapies to market, address global supply shortages and support therapeutic developers through rapid access to material. As new gene therapies are launched around the world with the potential to change lives, our investment is a further vote of confidence in the future of this exciting and transformative industry here in the UK.”

UK C&GT Industry

The UK is a global leader in the C&GT space, with the largest cluster of therapeutic development companies outside the US. UK investment in ATMPs for human use totalled at £3.8bn, resulting in nine therapies reimbursed and reaching patients, and 38 therapies in Phase III of clinical development at the end of 2021. By 2035, the UK is expected to have a 15% share of C&GT global market activity, contributing £10bn in revenue and providing 18,000 jobs.

Matthew Durdy, CEO, Cell and Gene Therapy Catapult: “The funding and launch of the new Charles River facility represents a powerful and vital addition to the national manufacturing network and marks a huge step forward for the UK’s infrastructure needs. The rapid expansion of our manufacturing capabilities is fundamental both to meeting the growing global demand for ATMPs and developing the UK’s standing as a leading international hub for cell and gene therapy.

Overcoming key challenges to further open up local and international market opportunities remains crucial to the sector’s continued growth. Moreover, world class manufacturing technology and robust supply chain solutions become increasingly pivotal as the market evolves to target these life-changing therapies at high prevalence diseases. Capabilities such as those now established at Alderley Park are central to addressing these challenges and to ensuring that the UK continues to excel and be a global leader in cell and gene therapies.”

Cell and Gene Therapies

C&GTs utilise genetic material, or live cells, to treat or potentially cure a disease, and can allow for the creation of highly personalized therapies with approved products already on the market for indications such as multiple myeloma, retinal dystrophy, and Spinal Muscular Atrophy (SMA). Advanced Therapy Medicinal Products (ATMPs) are widely regarded as having the potential to change the way we manage difficult, life-changing conditions including various cancers and neurological diseases such as Parkinson’s and Alzheimer’s, also demonstrating their importance in the development of COVID-19 vaccines.

To learn more about the expansion of Charles River’s Alderley Park facility, click here.

spot_imgspot_img

Latest

Rapist jailed after sending apology text to victim

A man who raped a woman - and then...

Places to pay your respects in Pendle on Remembrance Sunday

Pendle residents are invited to pay their respects to...

New Cabin Space Ltd. Introduces Affordable Portable Buildings

New Cabin Space Ltd, a newly launched provider of...

Rachel Reeves says budget will raise taxes by £40 billion

Chancellor Rachel Reeves says her budget will raise taxes...
spot_img

Subscribe to our newsletter

Business Lancashire will use the information you provide on this form to be in touch with you and to provide updates and marketing.

Don't miss

New Cabin Space Ltd. Introduces Affordable Portable Buildings

New Cabin Space Ltd, a newly launched provider of...

Bowker MINI staff join Ribble Rivers Trust for woodland maintenance

Bowker MINI employees have completed a volunteer day with...

Safety reminders issued for Pendle residents this Bonfire Night

As Bonfire Night approaches, Pendle Community Safety Partnership is...

Esin Akan’s 6-in-1 Bag Exceeds Kickstarter Target by 300%

The 6-in-1 Wimbledon Olive Leather Bag exceeds its Kickstarter...

More News

Epcy Links UK Patients to Leading Clinics in Turkey

Epcy, a leading platform for healthcare tourism, is now offering UK residents access to top-quality yet affordable medical treatments in Turkey. With a directory featuring...

Greater Lancashire Hospital expands services with six-figure MRI investment

Greater Lancashire Hospital is launching a new MRI (Magnetic Resonance Imaging) department to expand much-needed regional healthcare diagnostics provision through the NHS Choose and...

Village Gym Joins Forces with HYROX Global Fitness Challenge

Village Health & Wellness Clubs are known for staying ahead of the latest fitness trends, and their partnership with HYROX is no exception. As...